Bleomycin
Other Cytotoxic Antibiotics
- Drug class
- Other Cytotoxic Antibiotics
- Availability
- See label
- Routes
- Subcutaneous, Intracavitary
- Markets covered
- 2
- Products on record
- 6
Overview
Bleomycin is an active pharmaceutical ingredient in the Other Cytotoxic Antibiotics group (L01DC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | May 15, 2026 |
| CA Canada | Health Canada | 3 | April 7, 2026 |
GBUnited Kingdom· MHRA
3 products
Uses
Bleomycin can be used in the treatment of: • Squamous cell carcinoma (SCC) of the head and neck, cervix and external genitalia • Hodgkin's lymphoma • Non-Hodgkin’s lymphoma of intermediate and high malignancy in adults • Testicular carcinoma (seminoma and non-seminoma) • Intrapleural therapy of malignant pleural effusions.
Bleomycin can be used as a monotherapy, but is usually combined with other cytostatics and/or radiation therapy.
How to take
CACanada· Health Canada
3 products
Uses
AND CLINICAL USES
Bleomycin for Injection USP should be used as first-line therapy and/or adjuvant to surgery and radiation therapy.
It has been shown to be useful in the following neoplasms:
Squamous Cell Carcinoma: Skin, larynx and paralarynx, penis, cervix and vulva. Bleomycin in combination with radiotherapy shows improved results in lung cancer and cervical carcinoma.
Lymphomas:
Hodgkin's lymphoma and non-Hodgkin's lymphoma including reticulum cell sarcoma and lymphosarcoma. BACOP, M-BACOP, COP-BLAM and MACOP-B are used as first-line therapy in the treatment of diffuse large cell lymphoma. MOPP/ABVD is used as first-line therapy for Hodgkin's lymphoma.
Bleomycin is useful in Hodgkin's patients with disseminated disease (Stage IV) no longer treatable by bone marrow depressant agents. Bleomycin, added to the widely used MOPP regimen, increases the responses as well as survival rates of patients with advanced Hodgkin's disease; furthermore, bleomycin does not show cross-resistance to MOPP.
Drug interactions
Known interactions involving Bleomycin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL450430106 · revised April 17, 2026
- [2]Health Canada (DPD) · 02131692 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.